Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03DX Other systemic drugs for obstructive airway diseases
R03DX08 Reslizumab
D08985 Reslizumab (USAN) <US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Respiratory Tract Agents, Other
Immunomodulators
Reslizumab
D08985 Reslizumab (USAN)
Drug groups [BR:br08330]
Immunological agent
DG02019 Interleukin inhibitor
D08985 Reslizumab
Drug classes [BR:br08332]
Immunological agent
DG02019 Interleukin inhibitor
D08985 Reslizumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Interleukins
IL5
D08985 Reslizumab (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08985
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08985
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08985